PatentJun 8, 2026, 10:02 AM
Cosmos Health Subsidiary Acquires International Patent
AI Summary
Cosmos Health Inc. announced that its wholly owned subsidiary, Cana Laboratories S.A., has acquired international patent application WO2025108566A1 from Cloudpharm P.C. This acquisition is a significant step in expanding the company's nanotechnology investment initiatives and pursuing global patent protection. The underlying technology is set to support the development of next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare products, aligning with Cosmos Health's strategy to grow its intellectual property portfolio and strengthen vertical integration.
Key Highlights
- Cosmos Health's subsidiary, Cana Laboratories, acquired international patent application WO2025108566A1.
- The patent was acquired from Cloudpharm P.C.
- Cana Laboratories is pursuing national and regional patent protection in key international markets.
- The technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare products.
- This expands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing.
- The acquisition aligns with Cosmos Health's strategy to expand its IP portfolio and strengthen vertical integration.
Price Impact
More from COSM